How the FDA will spend your fees

Curious how the FDA might spend its PDUFA fees? A new five-year plan shows that FDA will plow the money into post-marketing safety to meet its commitments under the new law passed last fall. The agency would spend the to boost the number of employees looking at new scientific approaches to drug safety, improving adverse event detection and prevention programs, and cutting back on medication errors. Plus, it would invest millions in epidemiology "best practices" and data acquisition. Want more detail? Check out the plan itself on the FDA website.

- see the plan
- check out the story at FDA News

Related Articles:
FDA aims to hire 1,300 by October
FDA: Drugmakers responsible for safety
House passes PDUFA: bill heads to Senate
Panel: Give FDA power to recall

Suggested Articles

It’s final: England won’t be covering AZ’s quick-selling Tagrisso in previously untreated non-small cell lung cancer patients with EGFR mutatations.

Top J&J meds have managed to hang onto market share in the face of new generics and biosims, but the drugmaker expects the pain to continue in 2020.

Lonza’s search for a new CEO is expected to be wrapped up this year as the CDMO homes in on a list of veterans from outside the company.